Autologous NK cell infusions in treatment resistant Cancer - Protocol Description
If you (or someone you know) has metastatic cancer of the lung, prostate, colon, rectum, kidney, pancreas or malignant melanoma that is not responding to standard treatments, you may be able to participate in our clinical trial designed to evaluate the safety of a new type of cell therapy. Specifically, we are testing the safety and tolerability of the infusion of a type of your own white blood cells called NK cells.
In this research project, your NK cells will be collected, reproduced to large numbers in the laboratory and then be given back to you as an infusion. Before the cells are given back, you will receive two chemotherapy agents: pentostatin, to suppress your immune system and prevent it from attacking the infused NK cells, and bortezomib, to increase the anti-tumor activity of the NK cells. You will also receive the drug interleukin-2 to maintain NK cell activity. You are required to return to the Clinical Center for frequent safety monitoring over a 7 week period of protocol participation. If you respond you may have the option to continue NK cell infusions.
To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov